JP2013505205A5 - - Google Patents

Download PDF

Info

Publication number
JP2013505205A5
JP2013505205A5 JP2012529137A JP2012529137A JP2013505205A5 JP 2013505205 A5 JP2013505205 A5 JP 2013505205A5 JP 2012529137 A JP2012529137 A JP 2012529137A JP 2012529137 A JP2012529137 A JP 2012529137A JP 2013505205 A5 JP2013505205 A5 JP 2013505205A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
epratuzumab
administered
composition according
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012529137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505205A (ja
JP5816905B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/005225 external-priority patent/WO2011032633A1/en
Publication of JP2013505205A publication Critical patent/JP2013505205A/ja
Publication of JP2013505205A5 publication Critical patent/JP2013505205A5/ja
Application granted granted Critical
Publication of JP5816905B2 publication Critical patent/JP5816905B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012529137A 2009-09-18 2010-08-26 エプラツズマブを用いる自己免疫疾患及び炎症性疾患の治療 Expired - Fee Related JP5816905B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24379709P 2009-09-18 2009-09-18
US61/243,797 2009-09-18
PCT/EP2010/005225 WO2011032633A1 (en) 2009-09-18 2010-08-26 Treatment of autoimmune and inflammatory diseases with epratuzumab

Publications (3)

Publication Number Publication Date
JP2013505205A JP2013505205A (ja) 2013-02-14
JP2013505205A5 true JP2013505205A5 (2) 2013-09-26
JP5816905B2 JP5816905B2 (ja) 2015-11-18

Family

ID=43063209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012529137A Expired - Fee Related JP5816905B2 (ja) 2009-09-18 2010-08-26 エプラツズマブを用いる自己免疫疾患及び炎症性疾患の治療

Country Status (13)

Country Link
US (1) US20110070227A1 (2)
EP (1) EP2478012B1 (2)
JP (1) JP5816905B2 (2)
KR (1) KR20120100914A (2)
CN (1) CN102574920A (2)
AU (1) AU2010294905B2 (2)
BR (1) BR112012006035A2 (2)
CA (1) CA2774244A1 (2)
EA (1) EA026902B1 (2)
ES (1) ES2608661T3 (2)
IN (1) IN2012DN02196A (2)
MX (1) MX341117B (2)
WO (1) WO2011032633A1 (2)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
MX2010012473A (es) 2008-05-23 2011-02-23 Siwa Corp Metodos, composiciones y aparato para facilitar la regeneracion.
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
ES2649990T3 (es) * 2012-10-12 2018-01-16 Medimmune Limited Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 低密度リポタンパク質受容体をコードするポリヌクレオチド
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
CN107001459B (zh) 2014-09-19 2021-11-23 Siwa有限公司 用于治疗炎症和自身免疫紊乱的抗age抗体
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
PT3337829T (pt) 2016-02-19 2020-02-10 Siwa Corp Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
MX375569B (es) 2017-02-08 2025-03-04 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
PT3612537T (pt) 2017-04-18 2022-08-29 Medimmune Ltd Conjugados de pirrolobenzodiazepina
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
DK3668874T3 (da) 2017-08-18 2022-02-14 Medimmune Ltd Pyrrolobenzodiazepin-konjugater
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2020078454A1 (en) * 2018-10-18 2020-04-23 Sinomab Bioscience Limited Method of modulating autoimmunity by disrupting cis‐ligand binding of siglec type antigens
KR102890251B1 (ko) 2019-03-15 2025-11-25 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
ES2251723T3 (es) * 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
CA2375912C (en) * 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
CN101928344B (zh) * 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
EP2650306A1 (en) * 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
SI2032606T1 (sl) * 2006-05-30 2014-02-28 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
US8283162B2 (en) * 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof

Similar Documents

Publication Publication Date Title
JP2013505205A5 (2)
JP2015515475A5 (2)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2012193216A5 (2)
JP2006504795A5 (2)
JP2018193377A5 (2)
JP2016518387A5 (2)
JP2016512248A5 (2)
JP2013542247A5 (2)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
JP2011251975A5 (2)
JP2012515184A5 (2)
JP2012502909A5 (2)
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
JP2012533565A5 (2)
RU2009142937A (ru) Тапентадол для лечения в связи с остеоартрозом
JP2015537009A5 (2)
RU2016103764A (ru) Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан
JP2007238598A5 (2)
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
RU2013157398A (ru) Композиция
JP2011500589A5 (2)
JP2013540734A5 (2)
IL300144A (en) Benzazepines are combined for the treatment of Tourette syndrome
JP2014510780A5 (2)